Nucl Med Mol Imaging.  2020 Aug;54(4):168-174. 10.1007/s13139-020-00647-6.

Association Between Colonic¹⁸F-FDG Uptake and Glycemic Control in Patients with Diabetes Mellitus

• Chang HS
• Kim SJ
• Kim YH

• KMID: 2505755
• DOI: http://doi.org/10.1007/s13139-020-00647-6

Abstract

Purpose
Positron emission tomography/computed tomography (PET/CT) with ¹⁸F-fluorodeoxyglucose (FDG) is a useful imagingmodalitythat visualizes glucose utilization. Diffuse colonic FDG uptake is frequently observed in patients being treated fordiabetes mellitus (DM), especially with metformin. The aim of this study was to evaluate whether patients without increasedcolonic FDG uptake after taking oral hypoglycemic agents (OHA) are associated with insufficient glycemic control.
Methods
A total of 279 subjects who underwent FDG PET/CT scans for health examinations and had been diagnosed with DMand taken an OHA before the day of the FDG PET/CT were included. Colonic FDG uptake in the study subjects was visuallyassessed, and the maximal and mean standard uptake value (SUV) was measured. Fasting blood glucose and glycated hemoglobinA1c (HbA1c) levels at both baseline and follow-up visits as well as DM management were compared according to thecolonic FDG uptake.
Results
The mean age of study subjects was 48.8 years old, and 251 of subjects were male. Positive colonic FDG uptake wasobserved in 200 (71.7%) subjects. Fasting blood glucose and Hb1Ac levels on the day of FDG PET/CT were higher in subjectswithout positive colonic FDG uptake than those with positive colonic FDG uptake (p≤ 0.001). But there was no significantdifference between the two groups at follow-up visits.
Conclusions
Patients with DM who did not show increased colonic FDG uptake after taking OHA were associated with higherfasting blood glucose and HbA1c levels on the day of FDG PET/CT.

Keyword

¹⁸F-FDG; Diabetesmellitus; Oral hypoglycemic agent; Glycated hemoglobin A1c